

# Myocarditis Related-COVID-19 mRNA Vaccination: A Narrative Review

*by* Nany Hairunisa FK

---

**Submission date:** 18-Aug-2024 02:32PM (UTC+0700)

**Submission ID:** 2433631468

**File name:** Final\_Draft-AMJ-2304-1106\_Proofread.docx (353.99K)

**Word count:** 5499

**Character count:** 32276

# Myocarditis Related-COVID-19 mRNA Vaccination: A Narrative Review

**Running title:** Myocarditis Related-COVID-19 mRNA Vaccination

Idman Gushaendri <sup>1</sup>, Faiza Shafia <sup>1</sup>, Nany Hairunisa <sup>2\*</sup>, Emad Yousif <sup>3</sup>, Husnun Amalia <sup>4</sup>

**1** Medical professional study program, Faculty of Medicine, Universitas Trisakti, Jakarta, Indonesia.

**2** Department of Occupational Medicine, Faculty of Medicine, Universitas Trisakti, Jakarta, Indonesia.

**3** Department of Chemistry, College of Science, Al-Nahrain University, Baghdad, Iraq.

**4** Department of Ophthalmology, Faculty of Medicine, Universitas Trisakti, Jakarta, Indonesia

Received date: 13-4-2023

Accepted date: 30-5-2023

\*Corresponding Author

E-Mail: [nanyhairunisa@trisakti.ac.id](mailto:nanyhairunisa@trisakti.ac.id)

Phone number: 0062 8215417 1253

## Abstract

The unprecedented impact of the coronavirus disease-19 (COVID-19) pandemic on society and the global economy has highlighted the urgent need for an effective and safe vaccine. One of the very rare side effects of this vaccine is myocarditis, which was realized to be a terrible complication of the COVID-19 mRNA vaccine. A recent study showed an increase in 1824 events of myocarditis reported to VAERS, 383 (21.00%) reported after receiving a single dose of vaccine, then 956 (52.41%) after injection of the second dose. The most common complaint is chest pain that appears within 1 week after the injection. Young and male patients have a high incidence. The pathophysiology of post-mRNA vaccination myocarditis remains unclear, with one study hypothesizing it to be due to hypersensitivity myocarditis and another study suggesting another possible mechanism is molecular mimicry. The main aim of this literature review is to improve knowledge, prevention, management, and also determine the incidence between the COVID-19 mRNA vaccine and myocarditis.

**Keywords:** COVID-19; Myocarditis; COVID-19 mRNA vaccine

## Introduction

Worldwide pandemic coronavirus disease-19 (COVID-19) announced by World Health Organization (WHO) On 11 March 2020 [1]. All nations around the world struggle to maintain the spread the virus due to direct impact and absence of effective treatment, starting from organizing a call to quarantine and lockdown, socially distancing, and self-protecting by using a face mask [2], [3]. As of 12 January 2022, there are some vaccine released by WHO released the vaccines that have possess the WHO Emergency Use Listing Procedure (EUL), such as Moderna, Pfizer-BioNTech,

Sinovac Biotech, Johnson and Johnson, AstraZeneca–University of Oxford, Sinopharm, Nuvaxovid, and covovax [4] In addition being quite widespread in the world, useful, and safe, vaccination administration is faced with unexpected and rare side effects. Beyond usual symptom peri-injection fatigue, myalgias, and fevers, tracked the clinical trials, vaccine related myocarditis has emerged as an exceedingly rare adverse event [5], [6].

The most widely recognized incidence of myocarditis is related with mRNA vaccine following the second dose, nonetheless, these were generally a very rare occurrence at less than 10 for each 100,000 individuals [7]. The exact mechanism of this event is still not well known and must be investigated again, but the most likely is the binding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike proteins to angiotensin-converting enzyme 2 (ACE2) and then expressed on host cells in rhythm with host transmembrane serine protease 2 (TMPRSS2), this can lead to cell entry and viral infection [29].

The use of the SARS-CoV-2 spike protein to elicit an immune response is of greater concern because it can cause vaccine-associated myocarditis [9] The risk factors for developing myocarditis post COVID-19 vaccination is still unclear, it is suspected to be linked with gender, age, and genetic factor. Myocarditis is particularly seen in young adult and adolescent males aged 16 - 40 years present with the symptoms mostly within 1 week post vaccination [7], [9], [10]. Through June 11, 2021, 1226 probable myocarditis/pericarditis cases were reported to the Advisory Committee on Immunization Practices with 67% occurring after second dose mRNA vaccine. Predominant gender was male with a percentage of 79% and commonly appeared in people < 30 years [9]. Here we provide further details on the data, prevention, and management of events leading to myocarditis after vaccination with the COVID-19 mRNA vaccine.

## Methods

We conducted a literature review based on relevance to this topic. All databases were searched on Google Scholar, PubMed, and ResearchGate using the following keywords: 'COVID-19, myocarditis, COVID-19 mRNA vaccine'. Overall, 8 case reports related to COVID-19 mRNA vaccine induced myocarditis as well as several systematic reviews and literature reviews were found.

## Myocarditis

The occurrence of inflammation that causes weakness of the heart muscle or cardiomyopathy is said to be myocarditis associated with decreased cardiac function and ventricular remodeling diagnosed by established histological, immunological, and immunohistochemical criteria [11]–[13].

Myocarditis can occur due to non-infectious and infectious agents. Data since the last 4 decades, viral infection is considered the most frequent etiology, and examples of other etiologies can be infection (bacteria, spirochetes, parasites), autoimmune disturbance (autoimmune disease, sarcoidosis), and drug toxicity [13]. Coxsackie and Parvovirus B19 are the major causes of myocarditis in the United States and Europe [14] The incidence of myocarditis in the world reaches 10 to 20 cases per 100,000 population, Coxsackie B virus as the most common etiology, endomyocardial biopsy results show that 25% to 40% of patients have the virus, but in recent years coronaviruses have become a frequently discussed etiology [11], [15]

Myocarditis conditions affect all ages, ethnicities, and genders, sufferers are dominated by young people and adults and middle-aged people, and is also very high in men [11]. Symptoms such as fever, respiratory symptoms, gastroenteritis, and myalgia are the most common non-specific systemic symptoms. Chest pain (36.5%), heart failure (30.5%) and a combination of dyspnea, palpitations and transient fatigue (24.1%) were the most common symptoms with biopsy-proven myocarditis. Early manifestations such as ventricular tachycardia were rare and occurred in only 5% of patients [14]

Diagnosis of myocarditis can be difficult, it is usually done by excluding other diseases. Electrocardiography (ECG) is used as a screening tool and it shows various non-specific anomalies [16] Frequently appears as ST-segment elevation often in the inferior and lateral leads. Moreover, it shows as T-wave inversions, PR-segment depression, widespread ST-segment depressions, pathological Q waves, bundle branch block (new-onset), QT prolongation, bradycardia, tachycardia, atrioventricular block or ventricular arrhythmias [16]–[18] In addition to ECG, cardiac markers can be performed. Troponin I and T (TnI, TnT), creatine kinase, and CK-MB are usually assessed in suspected patients [18] Since the vast majority of TnI is associated with the myocyte contractile apparatus, it shows a higher sensitivity and specificity for diagnosis myocarditis and can be identified up to 14 days after, even though it is not specific for inflammatory-mediated myocyte injury [19] Markers of inflammation such as white blood cell, C-reactive protein, and erythrocyte sedimentation rate are also inflated in many cases of myocarditis [20]. Echocardiography can be utilized as a routine investigation to eliminate non-inflammatory cardiac disease and might be helpful while recognizing fulminant from acute myocarditis [14], [20], [21]. Echocardiographic findings that may occur in myocarditis include reduced left ventricular ejection fraction (LVEF), diastolic dysfunction, segmental wall motion abnormalities, increased cardiac wall thickness, abnormal echogenicity in the myocardium or pericardial effusion [21] Endomyocardial biopsy (EMB) is a gold standard test in diagnosing myocarditis yet appears to be insensitive, it is reported to diagnose myocarditis in just 25% of the cases [18] Cardiac magnetic resonance (CMR) imaging is used as a non-invasive diagnostic tool based on the Lake Louise Criteria (LLC): original LLC and 2018 LLC. The latest criteria has higher sensitivity than the original version [22]

### COVID-19 Vaccines

Though still based on the same principles, vaccine development has continued into the modern era, and the techniques for introducing antigens have changed [23] There are several types of vaccines currently available, for now the most modern platforms; mRNA vaccines, and other types exist, toxoid, recombinant, live attenuated, inactivated, subunit, polysaccharide, and conjugate [24]

The foundation of an mRNA vaccination is the idea that mRNA is an intermediary messenger that must be converted into an antigen after being introduced into host cell through a variety of mechanisms [25] There are some vaccines that in clinical trial as well such as ARCT-021 (Arcturus, USA), ARCoV (Abogen, China), LNP-nCoVsaRNA (Imperial College London, gland), CVnCoV (CurVac, Germany), and ChulaCoV19 mRNA vaccine [26] WHO released the vaccines that have obtained the WHO Emergency Use Listing Procedure (EUL), including Sinovac Biotech, Pfizer–BioNTech, Moderna, Sinopharm, AstraZeneca, Johnson and Johnson, Nuvaxovid, covovax [4] Two mRNA COVID-19 vaccines have been given a path to commercialization, taking advantage of their rapid adaptability and development, namely mRNA-1273 and BNT162b2 [26]

Frequent side effects include heat, discomfort, edema, and erythema at the injection site, fever and chills, weariness, headaches, decreased appetite, myalgia, arthralgia, significant adverse reactions anaphylaxis/anaphylactic shock, Bell's palsy, and there are also unconfirmed issues such as infertility, preterm labor, and autoimmune diseases [23], [27] Myocarditis and pericarditis incidents have been linked to the two COVID-19 mRNA vaccines from Moderna and Pfizer-BioNTech, according to recent reports from several studies [9], [28]–[30].

### Myocarditis Associated COVID-19 mRNA Vaccines

Prior to the implementation of COVID-19, myopericarditis was the cause of 0.1% of the 620,195 reports submitted to the Vaccine Adverse Event Reporting System (VAERS) between 1990 and 2018 [9] Around December 14, 2020 and August 31, 2021 there have been 1991 cases of myocarditis (391 of which also included pericarditis) post mRNA vaccination reported to VAERS [9]. Of these cases, 1626

met the criteria for probable or confirmed myocarditis, 208 did not meet the criteria and 157 others that needed more information [31] Those aged 20-39 years who received the second dose of COVID-19 mRNA vaccine were projected to have 12.6 cases of myocarditis per million doses [28] Another Israeli study with around 5.4 million vaccine recipients found that second-dose vaccination-related myocarditis had an incidence ratio of 5.34 per 100,000 people, with diagnosis primarily occurring in younger males [30] Consequently, for every million vaccines that had at least one dose of Comirnatym, there were roughly 48.09 occurrences of myocarditis and pericarditis. Around 1.6 million first doses and 1.5 million second doses of Spikevax have been given up to this point [15] There were 203.13 incidences of myocarditis and pericarditis recorded per million people who had taken at least one dose of Spikevax in the UK. Although most cases are common after mRNA vaccines and increased up to 4 times compared to the others [32], [33]

**Table 1:** Overview of the reviewed sources.

Authors	Country	Purpose	Design study	Summary points
M.E Oster et al. (2022) [31]	US	Report on cases of myocarditis after COVID-19 mRNA vaccine injection	Descriptive study	Data shows that of the 192,405,448 people who received a total of 354,100,845 mRNA-based COVID-19 vaccines in this study, there were 1991 reports of myocarditis to VAERS and 1626 of these reports met criteria for myocarditis cases. Most of these cases occurred in males, and most occurred after the injection of the second dose of the vaccine. The overall incidence of myocarditis after vaccination is still quite infrequent.
W. Woo et al. (2022) [28]	Korea	Provide comprehensive information on complications that do not often occur after the COVID-19 vaccine, and also provide people with information before they get vaccinated.	Systematic review	This study obtained 74 patients from a total of 24 sources that showed with myocarditis after COVID-19 mRNA vaccination. The authors found that the most patients (49.5%) were less than 20 years old and the majority were male. Symptoms usually appeared within a few days after vaccination, with chest pain being the most common. An excerpt from one of the source articles reported 148 cases of myocarditis among 10.4 million vaccinated people, with symptoms appearing within 30 days of receiving the mRNA vaccination.
J Montgomery et al. (2021) [34]	US	To explain myocarditis that occurs after COVID-19 vaccination in the health System.	Retrospective case series	The military stated that there have been more than 2.8 million doses of the COVID-19 mRNA vaccine during the making of this study. A total of 23 male patients and previously healthy military members with high fitness levels showed symptoms of myocarditis. The largest percentage of events were after the second dose of the COVID-19 mRNA vaccine.
S. Lane	UK	To summarize	Systematic	This study used 32 sources that met the

(2022)[35]

the data reported review  
by several  
countries to  
estimate the  
reporting rate,  
and better  
40 understand the  
risk factors for  
myocarditis and  
pericarditis after  
COVID-19  
mRNA vaccine  
injections.

criteria. A total of 18,204 myocarditis and pericarditis events were submitted to UK, US, and EU/EEA regulators within the study timeframe. Males had a high rate of 62.24%. In the UK and US, the rate was high at age < 40 years and after the second dose at 47.1%.

Myocarditis typically presents with symptoms of dyspnea, orthopnea, and chest discomfort, which are similar to those of heart failure [36] Relatively minor symptoms including cough, fever, and dyspnea might be brought on by COVID-19 by itself rather than myocarditis [36] Patients with COVID-19 myocarditis might, however, present in a variety of clinical ways. Many research studies have shown that data from myocarditis associated with mRNA vaccines mostly presented with chest pain [6], [9], [28], [37], [38] Patients were presented with cardiac symptoms such as chest pain or palpitations [37] The COVID-19 vaccine's most often reported local side effects were pain at the injection site, swelling, and redness. Symptoms of the systemic response included chills, myalgia, fatigue, and fever [9], [28], [39] A total of 1824 myocarditis occurrences were reported to VAERS; 956 (52.41%) occurred after the second dose and 383 (21.00%) occurred after the first [35] According to research, the second dose was documented more often in numerous works of literature, with an onset time range of one to two days [6], [29], [40] **Table 1** shows some summary data related to the incidence of myocarditis and related to immunization with the COVID-19 mRNA vaccine.

The pathophysiology of myocarditis post-mRNA vaccination is still unclear but it may be hypothesized due to myocarditis hypersensitivity [41] There was a study with military soldiers in 15 United States with a total of 23 subjects who were people with good fitness levels, but contracted myocarditis after receiving the COVID-19 mRNA vaccine, from the results of the study discussion said that the clinical course showed eosinophilic hypersensitivity myocarditis, which may be related to drug use or also to vaccines [34] The COVID-19 mRNA vaccines contain nucleoside-modified mRNA that can lessen innate immunogenicity; nevertheless, in people with certain genetic predispositions, the immune response to the mRNA may not be diminished and may instead result in aberrant activation of innate and acquired immunological responses. The dendritic cells recognize the vaccine's mRNA as an immunizing agent, activating Toll-like receptors, and starting pro-inflammatory cascades and immunological pathways to release cytokines [9], [42] Another potential mechanism is the cross-reactivity of the SARS-CoV-2 antibodies and myocardial myosin caused by the molecular mimicry between the spike (S) protein of SARS-CoV-2 and cardiac antigens. This may result in the increase of polyclonal B cells, the production of immunological complexes, and an inflammatory response in people who already have dysregulated immune pathways due to predisposition factors [9], [42], [43] The S glycoprotein of SARS-CoV-2 also plays a role in the mechanism of myocarditis. It enters the cells through the mRNA vaccines and binds to ACE2 causing a buildup of angiotensin II, a protein associated with inflammation, therefore initiate myocardial inflammation [42]

In the United States, patients with myocarditis after receiving COVID-19 vaccines can report to the VAERS and were categorized as probable and confirmed cases based on their symptoms and lab findings [9], [44] A study was conducted at 74 patients with myocarditis post vaccines, abnormal ECG

findings are seen in 87,8% of patients with the highest abnormality in the ST-segment, all patients present with an increase levels of cardiac enzyme, 86,4 % of patients had elevated C-reactive protein levels, and 67,8% of patients had CMR suggesting myocarditis based on LLC [28]

### Predisposing Factors

Starting the attack against the COVID-19 disease with vaccinations, the mortality rate and severity have drastically decreased. On the other hand, there are many reports of side effects, such as myocarditis as a cardiovascular complication. The ratio of the incidence of myocarditis in men and women reaches 1.7:1 [29]. Others data shown the majority of reported cases in males (90%) compared to females (10%)[45] This is also found in other regions such as America with 72.92% data and 60.75% in the EU [35]. The male predominance has been discussed in previous studies, and the reason is still unknown. Sex hormones are a widely discussed theory which are the factors that influence the differences that occur through their receptors in both immune cells and host cardiac tissues [9], [29], [45]. A key player in this process is the male hormone testosterone, which has a strong inhibitory effect on anti-inflammatory cells and a commitment to a Th1-type immune response. Another factor that increases the prevalence is under diagnosis in women. Estrogen also inhibits proinflammatory T cells, which results in a reduction in cell-mediated immune responses. Hence, sex hormone may help to explain both the predilection for men and the cardioselective nature of the autoimmunity caused by the COVID-19 vaccination [9], [29], [45]

In addition to gender, myocarditis after vaccination is more common at a young age which is the highest according to the data at the age of 18-24 years [46], [47] There have been case reports reporting young male patients who died with histological findings suggestive of myocarditis after COVID-19 mRNA vaccine but on the other hand there are also reports of death at an older age [48], [49]. In contrast with men, the incidence of myocarditis in women is more stable with age and without an increase in incidence during adolescence [50] Due to testosterone, post-vaccination myocarditis is more common in teenage boys, the same thing happens to post-menopausal women because of low estrogen levels at the age of 55-60 year. Progesterone is a protective factor against myocarditis [50], [51]

### Management and Prevention

Recommendations from the National Advisory Committee on Immunization (NACI) from Canada to minimize side effects with recommended doses of the Pfizer 30mcg mRNA vaccine at ages 12 to 29 years and for ages 12-17 years related to the risk of myocarditis NACI recommends a gap of 8 weeks between the first and second doses mRNA vaccine [33], [52] Another recommendation from Singapore for COVID-19 vaccination recommends avoiding strenuous exercise for 2 weeks after vaccination [33], [53] People who experience chest pain within a week after vaccination, especially considering the prevalence, namely young age and men should be suspicious of complications of myocarditis. Seeing that there are reports of complications of myocarditis, it is recommended that people who have risk factors have another examination 3 to 6 months after vaccination. In addition, patients diagnosed with myocarditis should also not engage in strenuous activities and competitive sports [31] Examination with cardiac MRI may be able to help the evaluation of the progression or improvement of myocarditis in patients, but it is still not known for sure.

Angiotensin-converting enzyme inhibitor,  $\beta$ -blocker, intravenous immunoglobulin and aspirin have been applied to some patients, this is due to left ventricular systolic dysfunction that occurs [47] In patients with good resolution of symptoms and normal cardiac biomarkers, therapy can be deferred. If there are persistent mild symptoms in the absence of hemodynamic instability, heart failure, and arrhythmia, then administration of non-steroidal anti-inflammatory drugs, colchicine, and steroids may be considered. In more severe conditions the use of intravenous steroids and intravenous immunoglobulin along with other cardiac or circulatory support measures may be considered in

patients with hemodynamic instability, heart failure, new onset arrhythmias, left ventricular dysfunction. Cardiologists should be involved for initial assessment, evaluation, treatment, and follow-up, as well as infectious disease specialists for consideration of subsequent immunizations [9] Diagnosis is important as myocarditis associated with COVID-19 mRNA vaccine and common myocarditis are very similar, which is important for future treatment. Initial evaluation, cardiac troponin levels and ECG should be performed, and examination of erythrocyte sedimentation rate and C-reactive protein may be helpful. Clinical findings and course, patient age, hemodynamic stability, heart rhythm, comorbidities, as well as other potential causes, determine the type of evaluation and management [31] There are no guidelines nor specific treatment data for myocarditis related to the COVID-19 mRNA vaccine. There is a meta-analysis showing the use of Intravenous Immunoglobulin (IVIG) as a management of acute myocarditis shows positive results and low mortality rates, this is attributed to IVIG and also steroids are immunosuppressive agents as well as immunomodulators and can reduce the specific immune response to SARS-CoV-2 triggered by the vaccine along with improvements in left ventricular ejection fraction. Other conditions such as in fulminant myocarditis patients given IVIG are even more noticeable where it is shown to significantly increase the survival rate of this dangerous condition [54], [55] Corticosteroids such as prednisolone, may be considered in treating viral myocarditis in the absence of viral replication [36] Other management options such as colchicine, NSAIDs, favipiravir and tocilizumab, have been used by different studies, so further research is needed [41], [47], [56] A condition that can worsen myocarditis associated with the COVID-19 mRNA vaccine is cytokine storm, if this occurs, the combination therapy of favipiravir and tocilizumab should be administered. Tocilizumab, an anti-IL-6 receptor monoclonal antibody, was tested in combination with the anti-viral, favipiravir, to treat COVID-19 patients with cytokine storm, which had a positive effect on patients and can be given to reduce inflammation due to cytokine storm [56]

## Conclusion

Myocarditis associated with the COVID-19 mRNA vaccine appears as a very rare side effect. There is considerable variation in the clinical findings of this condition, with some studies suggesting that the majority present with chest pain. Data shows high rates in young adults and adolescents. Further surveillance is initiated at 3 to 6 months after vaccination to assess health and functional status and cardiac outcomes. Although there are no definitive evidence-based recommendations for the management of myocarditis caused by mRNA vaccination, many data suggest that the initial evaluation and treatment of COVID-19 mRNA vaccine-associated myocarditis cases is similar to that of myocarditis cases in general. The presence of post-vaccination myocarditis should be considered by health workers so that they can prevent and manage it properly. In addition, with a low incidence rate and the benefits of vaccination in preventing COVID-19 outweighing the risks, but monitoring and further research must still be carried out to determine other benefits and potential risks.

## Ethical Declarations

### Acknowledgements

None.

### Ethics approval and consent to participate

Not needed.

### Consent for publication

Not applicable (no individual personal data included).



### Availability of data and material

This is a minireview article.

### Competing interests

The authors declare that there is no conflict of interest

### Funding

No funding

4

### Author contributions

All the authors listed have made a substantial, direct, and intellectual contribution to the work, and approved it for publication.

### References

- [1] "WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020," *World Health Organization*, 2020. <https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020> (accessed Jan. 13, 2023).
- [2] J. S. Tregoning, K. E. Flight, S. L. Higham, Z. Wang, and B. F. Pierce, "Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape," *Nature Reviews Immunology*, vol. 21, no. 10. Nature Research, pp. 626–636, Oct. 01, 2021. doi: 10.1038/s41577-021-00592-1.
- [3] A. G. Hadi, M. Kadhom, E. Yousif, and N. Hairunisa, "In COVID-19 time, how to protect myself and others? a review," *Jurnal Biomedika dan Kesehatan*, vol. 3, no. 3, pp. 153–158, Sep. 2020, doi: 10.18051/JBiomedKes.2020.v3.153-158.
- [4] "Coronavirus disease (COVID-19): Vaccines." [https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-\(covid-19\)-vaccines](https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-vaccines) (accessed Jan. 13, 2023).
- [5] L. R. Baden *et al.*, "Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.," *N Engl J Med*, vol. 384, no. 5, pp. 403–416, Feb. 2021, doi: 10.1056/NEJMoa2035389.
- [6] A. Fazlollahi *et al.*, "Cardiac complications following mRNA COVID-19 vaccines: A systematic review of case reports and case series," *Rev Med Virol*, vol. 32, no. 4, Jul. 2022, doi: 10.1002/rmv.2318.
- [7] Government Australian, "Guidance on Myocarditis and Pericarditis after mRNA COVID-19 Vaccines," 2022.
- [8] N. S. Hendren, M. H. Drazner, B. Bozkurt, and L. T. Cooper, "Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome," *Circulation*, vol. 141, no. 23, pp. 1903–1914, Jun. 2020, doi: 10.1161/CIRCULATIONAHA.120.047349.
- [9] B. Bozkurt, I. Kamat, and P. J. Hotez, "Myocarditis with COVID-19 mRNA Vaccines," *Circulation*, vol. 144, no. 6. Lippincott Williams and Wilkins, pp. 471–484, Aug. 10, 2021. doi: 10.1161/CIRCULATIONAHA.121.056135.
- [10] A. Luk *et al.*, "Myocarditis and Pericarditis After COVID-19 mRNA Vaccination: Practical Considerations for Care Providers," *Canadian Journal of Cardiology*, vol. 37, no. 10, pp. 1629–1634, Oct. 2021, doi: 10.1016/j.cjca.2021.08.001.

- [11] C. Tschöpe *et al.*, "Myocarditis and inflammatory cardiomyopathy: current evidence and future directions," *Nature Reviews Cardiology*, vol. 18, no. 3. Nature Research, pp. 169–193, Mar. 01, 2021. doi: 10.1038/s41569-020-00435-x.
- [12] A. L. P. Caforio *et al.*, "Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.," *Eur Heart J*, vol. 34, no. 33, pp. 2636–48, 2648a–2648d, Sep. 2013, doi: 10.1093/eurheartj/eh210.
- [13] A. Pollack, A. R. Kontorovich, V. Fuster, and G. W. Dec, "Viral myocarditis-diagnosis, treatment options, and current controversies," *Nature Reviews Cardiology*, vol. 12, no. 11. Nature Publishing Group, pp. 670–680, Nov. 01, 2015. doi: 10.1038/nrcardio.2015.108.
- [14] M. Olejniczak, M. Schwartz, E. Webber, A. Shaffer, and T. E. Perry, "Viral Myocarditis—Incidence, Diagnosis and Management," *Journal of Cardiothoracic and Vascular Anesthesia*, vol. 34, no. 6. W.B. Saunders, pp. 1591–1601, Jun. 01, 2020. doi: 10.1053/j.jvca.2019.12.052.
- [15] O. Narovlyanskaya and E. J. Winokur, "Viral Myocarditis," *Dimensions of Critical Care Nursing*, vol. 39, no. 2, pp. 75–80, Mar. 2020, doi: 10.1097/DCC.0000000000000402.
- [16] C. Buttà, L. Zappia, G. Lattera, and M. Roberto, "Diagnostic and prognostic role of electrocardiogram in acute myocarditis: A comprehensive review," *Annals of Noninvasive Electrocardiology*, vol. 25, no. 3, May 2020, doi: 10.1111/anec.12726.
- [17] M. Nassar *et al.*, "COVID-19 vaccine-induced myocarditis: Case report with literature review," *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*, vol. 15, no. 5, p. 102205, Sep. 2021, doi: 10.1016/j.dsx.2021.102205.
- [18] K. B. Lewandrowski, "Special Topics: Cardiac Markers in Myocarditis," *Clin Lab Med*, vol. 34, no. 1, pp. 129–135, Mar. 2014, doi: 10.1016/j.cll.2013.11.004.
- [19] S. C. Smith, J. H. Ladenson, J. W. Mason, and A. S. Jaffe, "Elevations of Cardiac Troponin I Associated With Myocarditis," *Circulation*, vol. 95, no. 1, pp. 163–168, Jan. 1997, doi: 10.1161/01.CIR.95.1.163.
- [20] W. Dwijanarko, H. Mumpuni, and B. Irawan, "Current Diagnosis and Management of Myocarditis."
- [21] T. Lampejo, S. M. Durkin, N. Bhatt, and O. Guttmann, "Acute myocarditis: aetiology, diagnosis and management," *Clinical Medicine*, vol. 21, no. 5, pp. e505–e510, Sep. 2021, doi: 10.7861/clinmed.2021-0121.
- [22] J. A. Luetkens *et al.*, "Comparison of Original and 2018 Lake Louise Criteria for Diagnosis of Acute Myocarditis: Results of a Validation Cohort," *Radiol Cardiothorac Imaging*, vol. 1, no. 3, p. e190010, Jul. 2019, doi: 10.1148/ryct.2019190010.
- [23] P. Anand and V. P. Stahel, "The safety of Covid-19 mRNA vaccines: a review," *Patient Saf Surg*, vol. 15, no. 1, p. 20, Dec. 2021, doi: 10.1186/s13037-021-00291-9.
- [24] S. Pascolo, "Synthetic Messenger RNA-Based Vaccines: From Scorn to Hype," *Viruses*, vol. 13, no. 2, p. 270, Feb. 2021, doi: 10.3390/v13020270.
- [25] J. W. Park, P. N. P. Lagniton, Y. Liu, and R.-H. Xu, "mRNA vaccines for COVID-19: what, why and how," *Int J Biol Sci*, vol. 17, no. 6, pp. 1446–1460, 2021, doi: 10.7150/ijbs.59233.
- [26] Q. Huang, J. Zeng, and J. Yan, "COVID-19 mRNA vaccines," *Journal of Genetics and Genomics*, vol. 48, no. 2, pp. 107–114, Feb. 2021, doi: 10.1016/j.jgg.2021.02.006.
- [27] O. Parés-Badell *et al.*, "Local and Systemic Adverse Reactions to mRNA COVID-19 Vaccines Comparing Two Vaccine Types and Occurrence of Previous COVID-19 Infection," *Vaccines (Basel)*, vol. 9, no. 12, p. 1463, Dec. 2021, doi: 10.3390/vaccines9121463.

- [28] W. Woo *et al.*, "Clinical characteristics and prognostic factors of myocarditis associated with the mRNA COVID-19 vaccine," *J Med Virol*, vol. 94, no. 4, pp. 1566–1580, Apr. 2022, doi: 10.1002/jmv.27501.
- [29] S. Abu Mouch *et al.*, "Myocarditis following COVID-19 mRNA vaccination," *Vaccine*, vol. 39, no. 29, pp. 3790–3793, Jun. 2021, doi: 10.1016/j.vaccine.2021.05.087.
- [30] R. Kornowski and G. Witberg, "Acute myocarditis caused by COVID-19 disease and following COVID-19 vaccination," *Open Heart*, vol. 9, no. 1. BMJ Publishing Group, Mar. 09, 2022. doi: 10.1136/openhrt-2021-001957.
- [31] M. E. Oster *et al.*, "Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021," *JAMA*, vol. 327, no. 4, p. 331, Jan. 2022, doi: 10.1001/jama.2021.24110.
- [32] S. Hassanzadeh, S. Sadeghi, A. Mirdamadi, and A. Nematollahi, "Myocarditis following AstraZeneca (an adenovirus vector vaccine) COVID-19 vaccination: A case report," *Clin Case Rep*, vol. 10, no. 4, Apr. 2022, doi: 10.1002/ccr3.5744.
- [33] R. R. Ling *et al.*, "Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: a systematic review and meta-analysis," *Lancet Respir Med*, vol. 10, no. 7, pp. 679–688, Jul. 2022, doi: 10.1016/S2213-2600(22)00059-5.
- [34] J. Montgomery *et al.*, "Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military," *JAMA Cardiol*, vol. 6, no. 10, p. 1202, Oct. 2021, doi: 10.1001/jamacardio.2021.2833.
- [35] S. Lane, A. Yeomans, and S. Shakir, "Reports of myocarditis and pericarditis following mRNA COVID-19 vaccination: A systematic review of spontaneously reported data from the UK, Europe and the USA and of the scientific literature," *BMJ Open*, vol. 12, no. 5. BMJ Publishing Group, May 25, 2022. doi: 10.1136/bmjopen-2021-059223.
- [36] M. Ali *et al.*, "COVID-19 and myocarditis: a review of literature," *Egyptian Heart Journal*, vol. 74, no. 1. Springer Science and Business Media Deutschland GmbH, Dec. 01, 2022. doi: 10.1186/s43044-022-00260-2.
- [37] S. Cushion, V. Arboleda, Y. Hasanain, M. Demory Beckler, P. Hardigan, and M. M. Kesselman, "Comorbidities and Symptomatology of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2)-Related Myocarditis and SARS-CoV-2 Vaccine-Related Myocarditis: A Review," *Cureus*, Apr. 2022, doi: 10.7759/cureus.24084.
- [38] A. Simone *et al.*, "Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older," *JAMA Intern Med*, vol. 181, no. 12, p. 1668, Dec. 2021, doi: 10.1001/jamainternmed.2021.5511.
- [39] D. Gubernot *et al.*, "U.S. Population-Based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines," *Vaccine*, vol. 39, no. 28, pp. 3666–3677, Jun. 2021, doi: 10.1016/j.vaccine.2021.05.016.
- [40] A. A. Shiravi, A. Ardekani, E. Sheikhabaehi, and K. Heshmat-Ghahdarjani, "Cardiovascular Complications of SARS-CoV-2 Vaccines: An Overview," *Cardiology and Therapy*, vol. 11, no. 1. Adis, pp. 13–21, Mar. 01, 2022. doi: 10.1007/s40119-021-00248-0.
- [41] A. Matta *et al.*, "Clinical Presentation and Outcomes of Myocarditis Post mRNA Vaccination: A Meta-Analysis and Systematic Review," *Cureus*, Nov. 2021, doi: 10.7759/cureus.19240.
- [42] M. Fraser *et al.*, "COVID-19-Associated Myocarditis: An Evolving Concern in Cardiology and Beyond," *Biology (Basel)*, vol. 11, no. 4, p. 520, Mar. 2022, doi: 10.3390/biology11040520.

- [43] S. Heymans and L. T. Cooper, "Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms," *Nat Rev Cardiol*, vol. 19, no. 2, pp. 75–77, Feb. 2022, doi: 10.1038/s41569-021-00662-w.
- [44] J. W. Gargano *et al.*, "Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021," *MMWR Morb Mortal Wkly Rep*, vol. 70, no. 27, pp. 977–982, Jul. 2021, doi: 10.15585/mmwr.mm7027e2.
- [45] J. H. Chen *et al.*, "COVID-19 Vaccine-Related Myocarditis: A Descriptive Study of 40 Case Reports," *Cureus*, Jan. 2022, doi: 10.7759/cureus.21740.
- [46] S. le Vu *et al.*, "Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines," *Nat Commun*, vol. 13, no. 1, p. 3633, Jun. 2022, doi: 10.1038/s41467-022-31401-5.
- [47] T. Licata and A. Clements, "Case Report of COVID-19 mRNA Vaccine-Associated Myocarditis.," *WMJ*, vol. 121, no. 3, pp. E50–E52, Oct. 2022.
- [48] S. Choi *et al.*, "Myocarditis-induced Sudden Death after BNT162b2 mRNA COVID-19 Vaccination in Korea: Case Report Focusing on Histopathological Findings," *J Korean Med Sci*, vol. 36, no. 40, 2021, doi: 10.3346/jkms.2021.36.e286.
- [49] A. K. Verma, K. J. Lavine, and C.-Y. Lin, "Myocarditis after Covid-19 mRNA Vaccination," *New England Journal of Medicine*, vol. 385, no. 14, pp. 1332–1334, Sep. 2021, doi: 10.1056/NEJMc2109975.
- [50] V. Kytö, J. Sipilä, and P. Rautava, "The effects of gender and age on occurrence of clinically suspected myocarditis in adulthood," *Heart*, vol. 99, no. 22, pp. 1681–1684, Nov. 2013, doi: 10.1136/heartjnl-2013-304449.
- [51] A. Arola, E. Pikkarainen, J. O. Sipilä, J. Pykäri, P. Rautava, and V. Kytö, "Occurrence and Features of Childhood Myocarditis: A Nationwide Study in Finland," *J Am Heart Assoc*, vol. 6, no. 11, Nov. 2017, doi: 10.1161/JAHA.116.005306.
- [52] Canada Government, "COVID-19 vaccine: Canadian Immunization Guide - Canada.ca," 2022. <https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html> (accessed Jan. 14, 2023).
- [53] Ministry of Health Singapore, "MOH | News Highlights," *Singapore*, 2021. <https://www.moh.gov.sg/news-highlights/details/expert-committee-on-covid-19-vaccination-statement-on-skin-reactions-after-vaccination-and-refraining-from-strenuous-physical-activity-after-vaccination> (accessed Jan. 14, 2023).
- [54] X. Huang, Y. Sun, G. Su, Y. Li, and X. Shuai, "Intravenous Immunoglobulin Therapy for Acute Myocarditis in Children and Adults.," *Int Heart J*, vol. 60, no. 2, pp. 359–365, Mar. 2019, doi: 10.1536/ihj.18-299.
- [55] B. B. Das, W. B. Moskowitz, M. B. Taylor, and A. Palmer, "children Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far?," 2021, doi: 10.3390/children.
- [56] H. Zhao *et al.*, "Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size," *Biomedicine & Pharmacotherapy*, vol. 133, p. 110825, Jan. 2021, doi: 10.1016/j.biopha.2020.110825.

# Myocarditis Related-COVID-19 mRNA Vaccination: A Narrative Review

## ORIGINALITY REPORT

18%

SIMILARITY INDEX

13%

INTERNET SOURCES

16%

PUBLICATIONS

6%

STUDENT PAPERS

## PRIMARY SOURCES

1	<a href="http://www.mdpi.com">www.mdpi.com</a> Internet Source	1%
2	<a href="http://jamanetwork.com">jamanetwork.com</a> Internet Source	1%
3	<a href="http://omronhealthcare.com">omronhealthcare.com</a> Internet Source	1%
4	<a href="http://www.frontiersin.org">www.frontiersin.org</a> Internet Source	1%
5	Submitted to Saint Mark's High School Student Paper	1%
6	Chung-Yen Chen, Ta-Chen Su. "Benefits and Harms of COVID-19 Vaccines in Cardiovascular Disease: A Comprehensive Review", Journal of Lipid and Atherosclerosis, 2023 Publication	1%
7	<a href="http://arro.anglia.ac.uk">arro.anglia.ac.uk</a> Internet Source	1%

8	Andreas P. Kalogeropoulos, Hal A. Skopicki, Javed Butler. "Heart Failure - An Essential Clinical Guide", CRC Press, 2022 Publication	1 %
9	Submitted to University of Anbar Student Paper	1 %
10	Submitted to Nightingale College - School of Nursing Student Paper	1 %
11	Susanna Esposito, Caterina Caminiti, Rosanna Giordano, Alberto Argentiero, Greta Ramundo, Nicola Principi. "Myocarditis Following COVID-19 Vaccine Use: Can It Play a Role for Conditioning Immunization Schedules?", Frontiers in Immunology, 2022 Publication	1 %
12	alies.pt Internet Source	1 %
13	www.coursehero.com Internet Source	1 %
14	Hamza Mimouni, Choukri Bahouh, Saida amaqdouf, Ilyass laaribi et al. "Cardiogenic shock revealing myocarditis after mRNA vaccination against covid-19: Case report and brief review for the first case in Morocco", Annals of Medicine and Surgery, 2021 Publication	<1 %

15	<a href="https://rcastoragev2.blob.core.windows.net">rcastoragev2.blob.core.windows.net</a> Internet Source	<1 %
16	<a href="https://valleyinternational.net">valleyinternational.net</a> Internet Source	<1 %
17	Congqin Chen, Chunmei Chen, Longxing Cao, Jie Fang, Jie Xiao. "Comparative safety profile of bivalent and original COVID-19 mRNA vaccines regarding myocarditis/pericarditis: A pharmacovigilance study", International Immunopharmacology, 2024 Publication	<1 %
18	<a href="https://iris.paho.org">iris.paho.org</a> Internet Source	<1 %
19	<a href="https://radiogeekbr.com.br">radiogeekbr.com.br</a> Internet Source	<1 %
20	Charlotte Switzer, Mark Loeb. "Evaluating the relationship between myocarditis and mRNA vaccination", Expert Review of Vaccines, 2021 Publication	<1 %
21	Ty J. Gluckman, Nicole M. Bhave, Larry A. Allen, Eugene H. Chung et al. "2022 ACC Expert Consensus Decision Pathway on Cardiovascular Sequelae of COVID-19 in Adults: Myocarditis and Other Myocardial Involvement, Post-Acute Sequelae of SARS-CoV-2 Infection, and Return to Play", Journal of the American College of Cardiology, 2022	<1 %

22

[pure.rug.nl](https://pure.rug.nl)  
Internet Source

<1 %

---

23

[www.ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov)  
Internet Source

<1 %

---

24

Ran Kornowski, Guy Witberg. "Acute myocarditis caused by COVID-19 disease and following COVID-19 vaccination", Open Heart, 2022  
Publication

<1 %

---

25

Submitted to University of Edinburgh  
Student Paper

<1 %

---

26

Bettina Heidecker, Noa Dagan, Ran Balicer, Urs Eriksson et al. " Myocarditis following -19 vaccine: incidence, presentation, diagnosis, pathophysiology, therapy, and outcomes put into perspective. A clinical consensus document supported by the Heart Failure Association of the European Society of Cardiology (ESC) and the ESC Working Group on Myocardial and Pericardial Diseases ", European Journal of Heart Failure, 2022  
Publication

<1 %

---

27

Christos Costa, Foteini Moniati. "The Epidemiology of COVID-19 Vaccine-Induced Myocarditis", Advances in Medicine, 2024  
Publication

<1 %

---



28	<a href="https://encyclopedia.pub">encyclopedia.pub</a> Internet Source	<1 %
29	<a href="https://www.mlo-online.com">www.mlo-online.com</a> Internet Source	<1 %
30	<a href="https://www.researchsquare.com">www.researchsquare.com</a> Internet Source	<1 %
31	John R. Power, Lucas K. Keyt, Eric D. Adler. "Myocarditis following COVID-19 vaccination: incidence, mechanisms, and clinical considerations", Expert Review of Cardiovascular Therapy, 2022 Publication	<1 %
32	<a href="https://publications.aap.org">publications.aap.org</a> Internet Source	<1 %
33	<a href="https://www.cureus.com">www.cureus.com</a> Internet Source	<1 %
34	<a href="https://www.scielo.br">www.scielo.br</a> Internet Source	<1 %
35	Nasim Naderi. "Cardiomyopathies and Myocarditis", Elsevier BV, 2022 Publication	<1 %
36	Qingrui Huang, Jiawei Zeng, Jinghua Yan. "COVID-19 mRNA vaccines", Journal of Genetics and Genomics, 2021 Publication	<1 %

37

Sarah Cushion, Vania Arboleda, Yousef Hasanain, Michelle Demory Beckler, Patrick Hardigan, Marc M Kesselman. "Comorbidities and Symptomatology of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2)-Related Myocarditis and SARS-CoV-2 Vaccine-Related Myocarditis: A Review", Cureus, 2022

Publication

<1 %

38

[academic.oup.com](https://academic.oup.com)

Internet Source

<1 %

39

[max-success.eu](https://max-success.eu)

Internet Source

<1 %

40

[www.bmj.com](https://www.bmj.com)

Internet Source

<1 %

Exclude quotes  Off

Exclude matches  < 10 words

Exclude bibliography  On

# Myocarditis Related-COVID-19 mRNA Vaccination: A Narrative Review

GRADEMARK REPORT

FINAL GRADE

GENERAL COMMENTS

**/0**

PAGE 1

PAGE 2

PAGE 3

PAGE 4

PAGE 5

PAGE 6

PAGE 7

PAGE 8

PAGE 9

PAGE 10

PAGE 11